In the process of clinical treatment for ovarian cancer patients, supplementing abdominal heat infusion chemotherapy on the basis of conventional tumor cytoreductive surgery can effectively improve both clinical symptoms and indicators of patients.
Ovarian cancer is mostly found in advanced stage, and tumor cytoreductive surgery and platinum-based chemotherapy are the main treatments for ovarian cancer, but the postoperative recurrence rate is still high, in which the residual micrometastatic lesions after surgery are the main factors of tumor recurrence. Intraoperative heat infusion chemotherapy is increasingly becoming an adjuvant treatment for ovarian cancer.
Intraperitoneal hyperthermic perfusion chemotherapy using paclitaxel and platinum drugs can significantly improve the prognosis of patients with advanced ovarian cancer, and there is no significant difference in efficacy between platinum-sensitive and platinum-resistant patients, which may be related to the thermal effect of intraperitoneal hyperthermic perfusion chemotherapy.
Whether it is necessary to use thermal perfusion chemotherapy to treat ovarian cancer should be decided after consulting with the attending physician, and actively cooperate with the doctor’s treatment in order to prolong the life span and improve the quality of life, and do not be discouraged so as not to make a mistake.
Please strictly follow the doctor’s prescription for medication and do not use medication on your own.